RT Journal Article
SR Electronic
T1 Genetic study of intrahepatic cholestasis of pregnancy in 101,023 Chinese women unveils East Asian-specific etiology linked to historic HBV infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.01.24309754
DO 10.1101/2024.07.01.24309754
A1 Liu, Yanhong
A1 Wei, Yuandan
A1 Chen, Xiaohang
A1 Huang, Shujia
A1 Gu, Yuqin
A1 Yang, Zijing
A1 Hu, Liang
A1 Guo, Xinxin
A1 Zheng, Hao
A1 Huang, Mingxi
A1 Chen, Shangliang
A1 Xiao, Tiantian
A1 Zhang, Yang
A1 Chen, Guo-Bo
A1 Xiong, Likuan
A1 Qiu, Xiu
A1 Wei, Fengxiang
A1 Zhen, Jianxin
A1 Liu, Siyang
YR 2024
UL http://medrxiv.org/content/early/2024/07/03/2024.07.01.24309754.abstract
AB Background & Aims Intrahepatic cholestasis of pregnancy (ICP) is the most common and high-risk liver disorder during the critical period of human reproduction. Despite varying prevalence across populations, a mechanistic understanding of this phenomenon is lacking. This study delves into the genetic etiology of ICP in East Asians, drawing comparisons with Europeans to comprehend ICP etiology in the context of genetic background and evolution. Methods We conducted the hitherto largest-scale genome-wide association studies (GWAS) on total bile acid concentration (TBA) and ICP among 101,023 Chinese pregnancies. The findings were subsequently replicated in two cohorts and compared with European populations. Additionally, phenome-wide association and spatio-temporal evolution analyses were employed to understand the function and explore evolutionary pattern of sites associated with ICP. Results We identified eight TBA and five ICP loci, including ten novel loci. Notably, we found an East-Asian-specific genetic locus at 14q24.1, contributing to a 6.41 μmol/L increase in TBA and a 15.23-fold higher risk of ICP per risk allele (95% CI: 15.10 to 15.36, P = 9.23×10-375). Phenome-wide association studies and spatial-temporal evolution analyses revealed that the 14q24.1 ICP risk locus exhibits resistance to hepatitis B infection and has become prevalent only within the last 3,000 years in East and Southeast Asia. Conclusions Our investigations have unraveled a distinct etiology of ICP between Europeans and East Asians, and has linked ICP etiology in East Asians to a historical HBV epidemic in East and Southeast Asia within the last 3,000 years. These findings lay the groundwork for an improved biological understanding of ICP pathophysiology. Further exploration and utilization of these variations hold the potential for more precise detection, assessment, and treatment of ICP.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by Shenzhen Basic Research Foundation (20220818100717002), Guangdong Basic and Applied Basic Research Foundation (2022B1515120080, 2020A1515110859), National Natural Science Foundation of China (31900487, 82203291), and the Shenzhen Health Elite Talent Training Project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee/IRB of the School of Public Health (Shenzhen) of Sun Yat-sen University gave ethical approval for this work. Ethics Committee/IRB of Longgang District Maternity and Child Healthcare Hospital of Shenzhen City gave ethical approval for this work. Ethics Committee/IRB of Shenzhen Baoan Women and Children Hospital gave ethical approval for this work. Ethics committee/IRB of the Human Genetic Resources Administration of China (HGRAC) gave approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesGWAS summary statistics for TBA and ICP phenotypes will be made publicly available in the GWAS catalog (https://www.ebi.ac.uk/gwas/) upon publication.